<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142515</url>
  </required_header>
  <id_info>
    <org_study_id>Local2019/RG-01</org_study_id>
    <nct_id>NCT04142515</nct_id>
  </id_info>
  <brief_title>Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)</brief_title>
  <acronym>CARTECEL</acronym>
  <official_title>Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated at Nîmes Carémeau University Hospital, for Giant Cells ARTEitis (Horton's Disease), for Diagnosis and During Long-term Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic)
      (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness.

      Treatment: corticosteroid therapy, which is effective in the vast majority of cases.

      Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first
      year for many patients, requiring a re-escalation of corticosteroid therapy, with its
      consequences:

        -  Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious
           morbidity.

        -  Requires additional immunosuppressive treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and paraclinical characteristics of patients diagnosed with ACG</measure>
    <time_frame>day 1</time_frame>
    <description>Describe the clinical and paraclinical characteristics of patients diagnosed with ACG to determine whether certain characteristics are significantly associated with a higher risk of developing corticosteroid dependence</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <condition>Horton Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 45 years or older with giant cell arteritis according to ACR criteria or
        revised criteria incorporating imaging parameters, managed at the University Hospital of
        Carémeau in Internal Medicine from 01/01/2011 to 01/01/2020.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 45 years or older

          -  Patients with giant cell arteritis according to ACR criteria or revised criteria
             incorporating imaging parameters,

          -  Patients managed at the University Hospital of Carémeau in Internal Medicine from
             01/01/2011 to 01/01/2020.

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Radjiv GOULABCHAND</last_name>
    <phone>0466686868</phone>
    <email>radjiv.GOULABCHAND@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHUNimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radjiv GOULABCHAND</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

